Stavudine in first-line antiretroviral regimens in resource-limited settings: time for a better solution-Reference-Cited by-同舟云学术

Stavudine in first-line antiretroviral regimens in resource-limited settings: time for a better solution

Published:2009-03 Issue:2 Volume:3 Page:109-111
ISSN:1758-4310
Container-title:HIV Therapy
language:en
Short-container-title:HIV Therapy

Author:

Bartlett John A¹,Maro Venance P²

Affiliation:

1. Box 3238, Duke University Medical Center, Durham, NC 27710, USA and, Kilimanjaro Christian Medical Centre, Kilimanjaro Christian Medical College, Tanzania.

2. Kilimanjaro Christian Medical Centre, Kilimanjaro Christian Medical College, Tanzania

Publisher

Future Medicine Ltd

Subject

Pharmacology (medical),Infectious Diseases,Virology,Dermatology,Drug Discovery,Pharmacology

Link

https://www.futuremedicine.com/doi/pdf/10.2217/17584310.3.2.109

Reference22 articles.

1. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance

2. KitahataM: Initiating rather than deferring HAART at a CD4+count betwen 351–500 cells/mm3is associated with improved survival. Presented at:48th Interscience Conference on Antimicrobial Agents and Chemotherapy.Washington, DC, USA, 25–28 October 2008 (Abstract H-869b).

3. Closing the Affordability Gap for Drugs in Low-Income Countries

4. Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized Trial

5. Zerit®, package insert. Bristol Myers Squibb, New York, NY, USA.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting of the Purine Biosynthesis Host Cell Pathway Enhances the Activity of Tenofovir Against Sensitive and Drug-Resistant HIV-1;Journal of Infectious Diseases;2013-08-06

2. The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications;HIV Therapy;2009-11